Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells

Leukemia Research

Volumn 36, Issue 9, 2012, Pages 1172-1178

  Yeom, Seon Yong ^a   Lee, Sook Ja ^a   Kim, Won Seog ^b   Park, Chaehwa ^a,b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bortezomib; Cell death; Leukemia; Lymphoma; Rad; Resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BORTEZOMIB; CASPASE 3; CYCLOSPORIN A; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; DRUG EFFICACY; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; LYMPHOMA CELL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; RAD GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; JURKAT CELLS; K562 CELLS; LEUKEMIA; LYMPHOMA; MITOCHONDRIA; PYRAZINES; RAS PROTEINS; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84864005031     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.05.004     Document Type: Article

References (40)

1. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003, 29(Suppl. l):33-39.
2. Pahler J.C., Ruiz S., Niemer I., et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003, 9:4570-4577.
3. Blum K.A., Johnson J.L., Niedzwiecki D., Canellos G.P., Cheson B.D., Bartlett N.L. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007, 48:1313-1319.
4. Zinzani P.L., Musuraca G., Tani M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:4293-4297.
5. Troch M., Jonak C., Müllauer L., et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009, 94:738-742.
6. Gerecitano J., Portlock C., Moskowitz C., et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 2009, 146:652-655.
7. Di Bella N., Taetle R., Kolibaba K., et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010, 115:475-480.
8. O'Connor O.A., Portlock C., Moskowitz C., et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010, 16:719-726.
9. Jung L., Holle L., Dalton W.S. Discovery, development, and clinical applications of bortezomib. Oncology (Willston Park) 2004, 18(14 Suppl. 11):4-13.
10. Chauhan D., Hideshima T., Anderson K.C. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 2005, 45:465-476.
11. Wei A.H., Roberts A.W. Bortezomib: putting mantle cell lymphoma on death row. Leuk Lymphoma 2008, 49:657-658.
12. Boccadoro M., Morgan G., Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005, 5:18.
13. Codony-Servat J., Tapia M.A., Bosch M., et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006, 5:665-675.
14. McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008, 11:164-179.
15. Rajkumar S.V., Domingo-Domenech J., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639.
16. Tang Z.Y., Wu Y.L., Gao S.L., Shen H.W. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J Surg Res 2008, 145:111-123.
17. Hideshima T., Ikeda H., Chauhan D., et al. Bortezomib induces canonical nuclear factor kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
18. Yang D.T., Young K.H., Kahl B.S., Markovina S., Miyamoto S. Prevalence of bortezomib resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 2008, 7:40.
19. Dolcet X., Llobet D., Encinas M., et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006, 281:22118-22130.
20. Gareau C., Fournier M.J., Filion C., et al. p21WAF1/CIP1 upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis. PLOS One 2011, 6(5):e20254.
21. Podar K., Gouill S.L., Zhang J., Opferman J.T., Zorn E., Tai Y.T., et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 2008, 27(6):721-731.
22. Smith A.J., Dai H., Correia C., Takahashi R., Lee S.H., Schmitz I., et al. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 2011, 286:17682-17692.
23. Wright J.J. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010, 16:4094-4104.
24. Tseng Y.H., Vicent D., Zhu J., et al. Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23. Cancer Res 2001, 61:2071-2079.
25. Moyers J.S., Bilan P.J., Zhu J., Kahn C.R. Rad and Rad-related GTPases interact with calmodulin and calmodulin-dependent protein kinase II. J Biol Chem 1997, 272:11832-11839.
26. Lee I., Yeom S.Y., Lee S.J., Kang W.K., Park C. A novel senescence-evasion mechanism involving Grap2 and cyclin D interacting protein inactivation by Ras associated with diabetes in cancer cells under doxorubicin treatment. Cancer Res 2010, 70:4357-4365.
27. Kim K., Ryu K., Kho Y., Park C. Effects of NF-kB inhibitors and its implication on NK/T Cell Lymphoma cells. Br J Haematol 2005, 131:59-66.
28. Kim J.H., Kim W.S., Yun Y., Park C. Epstein-barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1. Cell Signal 2010, 22:1858-1863.
29. Susin S.A., Zamzami N., Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998, 1366:151-165.
30. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615-2622.
31. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
32. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101:2377-2380.
33. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
34. Gatto S., Scappini B., Pham L., et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003, 88:853-863.
35. Chauhan D., Li G., Shringarpure R., et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003, 63:6174-6177.
36. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003, 2:835-843.
37. Bold R.J., Virudachalam S., McConkey D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001, 100:11-17.
38. Denlinger C.E., Rundall B.K., Keller M.D., Jones D.R. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004, 78:1207-1214.
39. Chen K.F., Yeh P.Y., Yeh K.H., Lu Y.S., Huang S.Y., Cheng A.L. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008, 68:6698-6707.
40. Pérez-Galán P., Roué G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.